Commonwealth Equity Services LLC Reduces Position in Exelixis, Inc. $EXEL

Posted by Brenda Bartman on Jun 7th, 2026

Commonwealth Equity Services LLC cut its holdings in shares of Exelixis, Inc. (NASDAQ:EXEL – Free Report) by 68.0% during the 4th quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 122,016 shares of the biotechnology company’s stock after selling 259,643 shares during the period. Commonwealth Equity Services LLC’s holdings in Exelixis were worth $5,348,000 at the end of the most recent reporting period.

Other institutional investors also recently modified their holdings of the company. BridgePort Financial Solutions LLC bought a new position in Exelixis in the third quarter valued at about $517,000. Candriam S.C.A. lifted its holdings in Exelixis by 18.4% in the third quarter. Candriam S.C.A. now owns 696,104 shares of the biotechnology company’s stock valued at $28,749,000 after acquiring an additional 108,367 shares during the period. Dimensional Fund Advisors LP lifted its holdings in Exelixis by 11.2% in the third quarter. Dimensional Fund Advisors LP now owns 4,180,912 shares of the biotechnology company’s stock valued at $172,658,000 after acquiring an additional 419,596 shares during the period. Illinois Municipal Retirement Fund lifted its holdings in Exelixis by 19.1% in the third quarter. Illinois Municipal Retirement Fund now owns 204,211 shares of the biotechnology company’s stock valued at $8,434,000 after acquiring an additional 32,737 shares during the period. Finally, Wealth Enhancement Advisory Services LLC lifted its holdings in Exelixis by 62.5% in the fourth quarter. Wealth Enhancement Advisory Services LLC now owns 187,154 shares of the biotechnology company’s stock valued at $8,224,000 after acquiring an additional 71,987 shares during the period. 85.27% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

EXEL has been the topic of a number of recent research reports. Truist Financial raised Exelixis to a “strong-buy” rating in a report on Monday, April 27th. Morgan Stanley increased their target price on Exelixis from $49.00 to $50.00 and gave the company an “equal weight” rating in a report on Wednesday, May 6th. TD Cowen increased their target price on Exelixis from $51.00 to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Barclays increased their target price on Exelixis from $44.00 to $45.00 and gave the company an “equal weight” rating in a report on Monday, April 20th. Finally, Stifel Nicolaus increased their target price on Exelixis from $44.00 to $47.00 and gave the company a “hold” rating in a report on Wednesday, May 6th. One analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, eleven have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to MarketBeat, Exelixis currently has an average rating of “Hold” and a consensus price target of $47.35.

Get Our Latest Stock Report on EXEL

Insider Transactions at Exelixis

In related news, Director Maria C. Freire sold 20,634 shares of Exelixis stock in a transaction that occurred on Thursday, May 7th. The stock was sold at an average price of $46.00, for a total transaction of $949,164.00. Following the sale, the director owned 100,819 shares of the company’s stock, valued at approximately $4,637,674. This trade represents a 16.99% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Patrick J. Haley sold 32,110 shares of Exelixis stock in a transaction that occurred on Wednesday, May 20th. The shares were sold at an average price of $49.81, for a total value of $1,599,399.10. Following the sale, the executive vice president directly owned 357,638 shares in the company, valued at $17,813,948.78. This trade represents a 8.24% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders have sold 219,170 shares of company stock valued at $10,620,641. Company insiders own 2.60% of the company’s stock.

Exelixis Stock Up 0.4%

NASDAQ EXEL opened at $52.70 on Friday. The stock’s 50-day moving average price is $46.96 and its 200-day moving average price is $44.53. Exelixis, Inc. has a 52 week low of $33.76 and a 52 week high of $52.98. The company has a market capitalization of $13.25 billion, a P/E ratio of 17.51, a price-to-earnings-growth ratio of 1.52 and a beta of 0.41.

Exelixis (NASDAQ:EXEL – Get Free Report) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported $0.87 EPS for the quarter, topping the consensus estimate of $0.75 by $0.12. Exelixis had a return on equity of 39.89% and a net margin of 35.08%.The firm had revenue of $610.81 million for the quarter, compared to the consensus estimate of $607.51 million. During the same quarter last year, the company earned $0.55 earnings per share. The business’s revenue for the quarter was up 10.0% compared to the same quarter last year. Research analysts anticipate that Exelixis, Inc. will post 3.16 EPS for the current year.

Exelixis Company Profile

(Free Report)

Exelixis, Inc is a biotechnology company specializing in the discovery, development and commercialization of small molecule therapies primarily for the treatment of cancer. Building on a platform that leverages model organism genetics and high-throughput screening, the company focuses its research on kinase inhibitors that modulate critical signaling pathways involved in tumor growth and metastasis. Exelixis’s translational research approach aims to advance novel compounds from early-stage discovery through clinical development and regulatory approval.

The company’s most recognized products include CABOMETYX® (cabozantinib), approved for the treatment of advanced renal cell carcinoma and hepatocellular carcinoma, and COMETRIQ® (cabozantinib) for metastatic medullary thyroid cancer.